HAE logo

HAEMONETICS CORP/MASS

HAENYSE
πŸ† #1349 by market capEarnings Nov 4US Equity
$129.41β–² $9.80 (+7.57%)
Simulated price
πŸ””
Track HAE
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 7.6%
7dβ–² 19.2%
14dβ–² 21.9%
30dβ–² 24.6%
ytdβ–² 61.6%
1yβ–² 168.8%
🏦Market Cap
$4.81B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-2.0%
Declining
πŸ“ŠGross Margin
57.4%
Healthy
πŸ’΅FCF Margin
21.5%
Strong
βš–οΈP/S Ratio
3.6x
Fair
Otter Score
76
Good

Trading Snapshot

Day Range
$127.45 – $130.12
52-Week Range
$47.56 – $110.45
Volume
$1.69B
Avg Volume
$1.55B
Shares Outstanding
45.4M
Next Earnings
Dec 6, 2026

Fundamentals Snapshot

Annual Revenue
$1.33B
Last Q Revenue
$339M
P/E Ratio
51.4
P/S Ratio
3.6x
EPS (TTM)
$2.12
Dividend Yield
0.00%
Dilution (1yr)
βˆ’2.7%

Why Investors Own HAE

  • βœ“High-growth profile β€” revenue up +14.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 64% gross margin and 16% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HAE logo

HAEMONETICS CORP/MASS

HAE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.3Bβ–Ό βˆ’2.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
55.7%β–Ό βˆ’2.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$241Mβ–² +8.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$260Mβ–² +82.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
45.7Mβ–Ό βˆ’2.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$951Mβ–Ό βˆ’$89M YoY
StockOtter Β· stockotter.space

About HAEMONETICS CORP/MASS

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Ratings

β“˜
Consensus
Buy
15 analysts
Strong Buy5
Buy6
Hold4
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates